What is the Fiscal Year for Black Diamond Therapeutics?
Date: November 13, 2026
Black Diamond Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Cambridge, MA
Industry
Biotechnology Research
Stock Symbol
BDTX
Description
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing silevertinib, a potent, brain penetrant fourth-generation EGFR inhibitor for patients with non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Black Diamond Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.